Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 436 to 450 of 563 results for oral care

  1. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  2. AposHealth for knee osteoarthritis (HTG671)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

  3. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

    Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

  4. PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)

    NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .

  5. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

  6. Risdiplam for treating spinal muscular atrophy (TA755)

    Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.

  7. What is the effectiveness and cost effectiveness of intravenous compared with oral antibiotics for preventing postnatal infections after birth with forceps or ventouse?

    is the effectiveness and cost effectiveness of intravenous compared with oral antibiotics for preventing postnatal infections after...

  8. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

  9. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.

  10. Natural Cycles for monitoring fertility (MIB244)

    NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .

  11. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

  12. Biodegradable subacromial spacer insertion for rotator cuff tears (IPG775)

    Evidence-based recommendations on biodegradable subacromial spacer insertion for rotator cuff tears. This involves inserting a balloon-shaped device between the top of the shoulder blade and the upper arm bone to reduce pain and improve shoulder function.

  13. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.

  14. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

  15. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTG713)

    Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.